HealthQuill Tumour
France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology medicine for a rare disease and expand the company’s portfolio.
Drugs Health Pharma

Sanofi to acquire Blueprint for $9.1b for immunology medicine

HQ Team June 2, 2025: France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology.

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Drugs Health Pharma

Merck’s pill to treat rare type of tumour gets approval from US regulator

HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a.

Read More
Tumour molecules can rob the human body’s immune cells to deprive them of their energy to fuel the invaders’ own needs, researchers find.
Drugs Health Pharma

Vampiric tumour cells can hijack human body’s immune cell energy

HQ Team November 22, 2023: Tumour molecules can rob the human body’s immune cells to deprive them of their energy to fuel the.

Read More
Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals, has got investigational new drug clearance from the FDA to conduct clinical trials in the US sites for its drug to treat advanced solid tumours and lymphomas.
Drugs Medical Pharma

Glenmark gets FDA nod for trials in US on tumour, cancer patients

Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals, has got investigational new drug clearance from the FDA to conduct clinical trials in.

Read More